• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

Introduction to (2R)-3-Cyclopropylbutan-2-amine (CAS No. 2248212-74-8)

(2R)-3-Cyclopropylbutan-2-amine, with the CAS number 2248212-74-8, is a chiral amine compound that has garnered significant attention in recent years due to its potential applications in pharmaceutical and chemical research. This compound is characterized by its unique structural features, including a cyclopropyl group and a chiral center, which contribute to its distinct chemical and biological properties.

The chiral nature of (2R)-3-Cyclopropylbutan-2-amine makes it particularly valuable in the synthesis of enantiomerically pure compounds, which are essential in the development of chiral drugs. The ability to control the stereochemistry of molecules is crucial in pharmaceutical research, as different enantiomers can exhibit significantly different biological activities. For instance, one enantiomer may be therapeutically active while the other may be inactive or even toxic.

Recent studies have highlighted the importance of cyclopropyl groups in enhancing the pharmacological properties of various compounds. The cyclopropyl moiety can influence the conformational flexibility and electronic properties of molecules, leading to improved binding affinities and selectivities. In the case of (2R)-3-Cyclopropylbutan-2-amine, the presence of this group may enhance its interactions with specific biological targets, such as receptors or enzymes.

The synthesis of (2R)-3-Cyclopropylbutan-2-amine has been extensively studied, with several efficient and scalable methods reported in the literature. One notable approach involves the asymmetric hydrogenation of a prochiral ketone precursor, followed by reductive amination to introduce the amine functionality. This method not only provides high yields but also ensures excellent enantioselectivity, making it suitable for large-scale production.

In terms of biological activity, (2R)-3-Cyclopropylbutan-2-amine has shown promising results in preliminary studies. It has been evaluated for its potential as a modulator of various neurotransmitter systems, including serotonin and dopamine. These neurotransmitters play critical roles in regulating mood, cognition, and other physiological processes. The compound's ability to interact with these systems could make it a valuable lead compound for the development of new therapeutic agents for neurological and psychiatric disorders.

Furthermore, pharmacokinetic studies have provided insights into the absorption, distribution, metabolism, and excretion (ADME) properties of (2R)-3-Cyclopropylbutan-2-amine. These studies are essential for understanding how the compound behaves in vivo and for optimizing its therapeutic potential. Initial findings suggest that the compound has favorable pharmacokinetic properties, including good oral bioavailability and a reasonable half-life, which are desirable attributes for drug candidates.

The safety profile of (2R)-3-Cyclopropylbutan-2-amine is another important aspect that has been investigated. Preclinical toxicity studies have shown that the compound is well-tolerated at therapeutic doses and does not exhibit significant adverse effects. However, further research is needed to fully assess its safety and efficacy in human subjects.

In conclusion, (2R)-3-Cyclopropylbutan-2-amine (CAS No. 2248212-74-8) represents a promising compound with potential applications in pharmaceutical research and development. Its unique structural features and favorable biological properties make it an attractive candidate for further investigation. As research in this area continues to advance, it is likely that new insights and applications will emerge, further highlighting the importance of this compound in the field of medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)